AbioMed touts improved survival, native heart recovery with Impella Quality Assurance Program
Abiomed (NSDQ:ABMD) presented data at ACC 2017 from its Impella Quality Assurance Program, touting an association between the use of best practice protocols and improved survival and native heart recovery as compared to inconsistent treatment or inexperienced hospitals.
Data came from the company’s IQ Database and cVAD Registry which included approximately 50,000 US patients, with a subset of 15,259 patients with acute myocardial infarction cardiogenic shock.
Results indicated that since the company’s Impella line of heart pumps received FDA pre-market approval in April 2016, there has been a 14% relative improvement in survival compared to the previous year.
“The FDA deemed Impella devices safe and effective in the U.S. for cardiogenic shock less than one year ago, which has allowed us to collaborate with hospitals to expand education on hemodynamic science and share best practices to achieve native heart recovery across the country. We are pleased to see improvements of 14 percent this year and recognize the opportunity to further impact and improve the outcomes of thousands of patients with the lessons learned by the most advanced centers and physicians,” Abiomed chief medical officer Dr. Seth Bilazarian said in a press release.